Filing Flows › GeneDx Holdings (WGS) › Q2 2025
GeneDx Holdings (WGS) Q2 2025 earnings results (second quarter 2025)
10-Q filed Jul 29, 2025
GeneDx Holdings (WGS) reported revenue of $103M for the second quarter 2025 (Q2 2025), +46% from a year earlier and +18% from the quarter before. Operating margin was 8.7%, net earnings $10.8M (10.5% of revenue).
GeneDx Holdings, Q2 2025: revenue $103M (+46% year over year), operating margin 8.7%, net earnings $10.8M, operating cash flow $10.4M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $103M | +18% | +46% |
| Gross profit | $70.9M | +21% | +65% |
| Operating profit | $9.0M | — | — |
| Net earnings | $10.8M | — | — |
| Operating cash flow | $10.4M | +2% | — |
| Free cash flow | $8.1M | +99% | — |
What changed
Revenue was $102.7M in Q2 2025, up 46% year over year and up 18% from the previous quarter. Patients with third-party insurance was the largest line at 79% of revenue. Patients with third-party insurance added $29.1M year over year (up 56%), 90% of the total change. Self-pay patients declined 51%.
Gross margin was 69.0%, up 8.1 points from a year earlier. Operating profit was $9.0M, a 8.7% margin (up 23.7 points year over year). Operating expenses grew 16% against revenue growth of 46%. The fastest-growing cost line was Research & development (+38%). Net earnings were $10.8M. The effective tax rate was -2.3%.
Operating cash flow was $10.4M, 96% of net earnings. Non-cash charges added back $6.2M of depreciation and amortization and $7.8M of share-based compensation. Working capital and other items used $14.4M. Capital expenditures of $2.4M left free cash flow of $8.1M.
Questions
What was GeneDx Holdings' revenue in the second quarter 2025?
GeneDx Holdings (WGS) reported revenue of $103M for the second quarter 2025 (Q2 2025), +46% from a year earlier and +18% from the quarter before.
Was GeneDx Holdings profitable in the second quarter 2025?
Operating profit was $9.0M (8.7% of revenue) and net earnings $10.8M.
Source: GeneDx Holdings 10-Q on SEC EDGAR.